Patients with NSCLC who have specific EGFR mutations, including the T790M resistance mutation, are the primary beneficiaries of osimertinib. It is often prescribed after the failure of prior EGFR tyrosine kinase inhibitor (TKI) therapies. Additionally, it is approved for use as a first-line treatment for patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations.
